the cellular uptake and degradation of apoE-containing lipoprotein particles (1-3). There is also evidence that apoE is necessary for efficient conversion of VLDL to IDL, and finally to LDL (4). ApoE thus plays an important role in the metabolism of plasma lipoproteins, a concept reinforced by recent studies in transgenic mice, in which the apoE gene was either overexpressed (5, 6) or knocked out (7) (8) (9) . ApoE is a genetically polymorphic plasma protein of 299 amino acid residues (10). The three major alleles of apoE at a single gene locus, located on chromosome 19, code for three major isoforms of apoE-apoE2, E3, and E4-which differ slightly in amino acid content and can be distinguished by isoelectric focusmg (11-13). Three homozygous phenotypes (apoE2/2, E3/3, and E4/4) and three heterozygous phenotypes (apoE3/2, E4/3, and E412) arise from the expression of any two of the three alleles (14). ApoE2 diers from apoE3, the most common form, by a substitution of cysteine for arginine at residue 158. Whereas #{225}poE3 and apoE4 bind normally to the apoB,E (LDL) receptor, apoE2 is defective in interacting with this receptor (<2% of the receptor binding activity of apoE3) (15) (16) (17) (18) 
the cellular uptake and degradation of apoE-containing lipoprotein particles (1) (2) (3) . There is also evidence that apoE is necessary for efficient conversion of VLDL to IDL, and finally to LDL (4). ApoE thus plays an important role in the metabolism of plasma lipoproteins, a concept reinforced by recent studies in transgenic mice, in which the apoE gene was either overexpressed (5, 6) or knocked out (7) (8) (9) . ApoE is a genetically polymorphic plasma protein of 299 amino acid residues (10). The three major alleles of apoE at a single gene locus, located on chromosome 19, code for three major isoforms of apoE-apoE2, E3, and E4-which differ slightly in amino acid content and can be distinguished by isoelectric focusmg (11-13). Three homozygous phenotypes (apoE2/2, E3/3, and E4/4) and three heterozygous phenotypes (apoE3/2, E4/3, and E412) arise from the expression of any two of the three alleles (14). ApoE2 diers from apoE3, the most common form, by a substitution of cysteine for arginine at residue 158. Whereas #{225}poE3 and apoE4 bind normally to the apoB,E (LDL) receptor, apoE2 is defective in interacting with this receptor (<2% of the receptor binding activity of apoE3) (15) (16) (17) (18) . The apoE2/2 phenotype is associated with fami!ial dysbetalipoproteinemia (FD) (19) (20) (21) .
The defective apoE is the underlying genetic defect responsible for the lipoprotein abnormalities of FD; the normal catabolism of chylomicrons, VLDLs, and IDL is disrupted, resulting in the accumulation of these lipoproteins in plasma (1) (2) (3) . However, most individuals who have the apoE2I2 phenotype are normocholesterolemic (2), with only 1-4% developing hypercholesterolemia, most probably jecause of additional genetic and (or) environmental factors (1) (2) (3) 20 However, to gain further insight into the physiological role of apoE and the mechanism of development of HFD, both normocholesterolemic FD (NFD) and HFD subjects homozygous for apoE2(Arg1-Cys) should be evaluated.
Therefore, in this study we com-pared the plasma lipoprotein profiles of 15 NTh individuals with those of 15 HFD individuals.
MaterIals and Methods

Subjects
All individuals described in this study were analyzed in the Lipid Clinic of the Leiden University Hospital between July 1989 and September 1992. During the study period we evaluated 15 normocholesterolemic individuals (plasma cholesterol concentration <6.5 mmol/L) and 28 hypercholesterolemic patients (plasma cholesterol concentration >7.0 mmol/L), all with the apoE2/2 phenotype, i.e., homozygous for apoE2(Arg1-*Cys), as determined by apoE genotyping.
The 15 subjects with NFD were matched for age and sex with 15 patients with HFD. We discovered 12 patients with HFD during routine apoE phenotype screening for the hypercholesterolemic patients referred to the Lipid Clinic; three other patients with HFD were identified during screening of the family members of these probands.
Six men with NFD, originally identified in a study by Smit et al. (23), were reanalyzed for the present study. Nine more individuals with NFl) were discovered during screening of family members of patients with HFD or subjects with NFL).
All individuals were investigated according to a stan- 
Separation of Lipoproteins
Blood samples were taken in the morning after >12 h of fasting. Plasma was obtained by centrifugation at l000g for 10 mm at room temperature <4 h after sampling. The separation of lipoproteins was started the day of blood collection with a two-step density gradient ultracentrifugation technique (22, 24) . In the first step, I{DL, LDL, IDL, and VLDL were separated. This gradient consisted of 2 mL of serum sample (adjusted to a density of 1.2 10 kg/L by adding solid KBr) on the bottom of a polyallomer tube (14 mL; Kontron, ZUrich, Switzerland), overlayered by 6 mL of a 1.030 kg/L solution and 4 mL of a 1.006 kg/L solution. After preparation of the gradient, the sample was centrifuged immediately at 210 000g for 24 h at 15#{176}C in a TST swinging-bucket rotor in a Centrikon T-2070 ultracentrifuge (Kontron). In the second step, VLDL was further separated into two subfractions, VLDL1 (large VLDL) and VLDL2 (small VLDL). The gradient for this consisted of 2 mL of VLDL solution (obtained by routine ultracentrifugation and adjusted to a density of 1.210 kg(L by adding solid KBr) on the bottom of the tube, overlayered by 2 mL of a 1.100 kgfL solution, 4 mL of a 1.040 kgfL solution, and 4 mL of a 1.006 kglL solution. This gradient was ultracentrifuged at 210 000g for 2 h at 15#{176}C in the same rotor and ultracentrifuge as in the first step. The gradients were fractionated with a specially designed fractionator (25) connected to a micropump and a fraction collector (LKB, Bromma, Sweden).
Chemical Analysis
The cholesterol concentration was determined in each fraction of both gradients. After incubation, the LDL was precipitated by Mn2, according to Morton and Zilversmit (30), and the radioactivity of the HDL was determined.
The activities of LCAT and CETP were measured in plasma that had been stored at -80#{176}C. The measured activities varied linearly with the amount of plasma used in the incubations.
All assays were performed in duplicate. The within-day CVs were 4.5% for LCAT and 2.7% for CETP. The measured activities reflect the activity of the enzyme and transfer protein as such (measured under optimal conditions) and are independent of endogenous plasma lipoproteins. The activities were related to the activity in a human plasma pool and expressed as a percentage of the activity in the plasma pool (arbitrary units).
ApoE Phenotyping and Genotyping
The apoE phenotype was determined by isoelectric focusing of delipidated plasma samples before and after 
Results
The apoE2/2 phenotype in plasma of all subjects with FL) (both HFD and NFL)) and the apoE4/3, E4/2, E3/3, or E3/2 phenotype in plasma of the normolipidemic controls were modified completely by prior treatment of the plasma sample with cysteamine;
i.e., the apoE4/3, E4/2, E3/3, E3/2, and E2/2 phenotypes were converted to the apoE4/4 phenotype. All subjects with FD were homozygous for apoE2(Arg158-Cys), and no additional rare apoE mutants were detected.
In light of evidence that various endogenous and exogenous factors may influence the plasma lipoprotein proffles in patients with HFD, we analyzed in detail several clinical and biochemical characteristics of these subjects. None of the patients was substantially overweight (body mass index >95th percentile), reported unusual dietary habits, or showed clinical or biochemical signs of concomitant disease.
As shown in Table 1 The lipoprotein profiles in plasma of the patients with HFD, the subjects with NFD, and the normolipidemic controls were analyzed by density gradient ultracentrifugation. In the typical plasma lipoprotein profiles presented in Fig. 1 , the patient with HFD and the subject with NFD had similar abnormalities in their lipoprotein profiles, but the absolute quantities of the abnormalities were less in the subject with NFD than in the patient with HFD.
The mean cholesterol concentrations of lipoprotein (sub)classes in plasma are presented in Table 2 . The patients with HFD and the subjects with NFD had significantly higher cholesterol concentrations of VLDL1, VLDL2, and IDL, and significantly lower cholesterol concentrations of LDL than did the normolipidemic controls. The HDL-cholesterol concentration was reduced in patients with HFD, but subjects with NFD and normolipidemic controls had similar concentrations. (Fig. 2) . In normolipidemic controls LDL was the major contributor (mean 61% of total cholesterol) to total cholesterol concentration, whereas VLDL1, VLDL2, and IDL (together 17% of total cholesterol) were only minor contributors.
In NFL) and HFD, however, 42% and 72%, respectively, of the total plasma cholesterol concentration was recovered in the VLDL1 +VLDL2+IDL fractions.
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Fraction number The relations between the total cholesterol concentration and the cholesterol concentrations of lipoproteins (VLDL1, VLDL2, IDL, and LDL) in plasma of patients with HFD and subjects with NFD were statistically analyzed (Fig. 3) . For reasons of clarity, the correlations are shown for HFD and NFD subjects in combination. The cholesterol concentrations of VLDL1 and VLDL2 were correlated to the total cholesterol concentration in plasma of patients with HFD (for VLDL1, r = 0.708, P <0.01; for VLDL2, r = 0.940, P <0.001) and subjects with NFD (r = 0.69 1 for VLDL1 and 0.730 for VLDL2, both P <0.01). Also, the IDL-cholesterol concentration was correlated to total cholesterol concentration in plasma of patients with HFD (r = 0.592, P <0.05) and subjects with NFD (r = 0.825, P <0.001). However, the LDL-choleaterol concentrations in plasma of subjects with HFD or NFD were not correlated to total cholesterol concentration (r = -0.136 and 0.306, respectively). The chemical composition of the lipoprotein fractions isolated by density gradient ultracentrifugation was analyzed. We found many differences in the composition of VLDL1, VLDL2, IDL, and LDL between patients with HFD, subjects with NFD, and normolipidemic controls (Table 3) . However, in agreement with a previous report (22), the most significant differences in the composition Note different ordinatescale forVLDL2 (B). ns, notsignificant. The plasma activities of CETP and LCAT were also measured.
Patients with HFD had a significantly higher mean activity of CETP than did subjects with NFD, whose activity was in turn higher than that in normolipidemic subjects (Table 4 ). The mean activity of LCAT in HFD was also significantly higher than that in normolipidemic subjects. In the plasma of 29 subjects with FD, CETP activity was correlated to the concentrations of VLDL1-cholesterol (r = 0.537, P <0.01), plasma total cholesterol (r = 0.520, P <0.01), VLDL2-cholesterol (r = 0.506, P <0.01), ILL-cholesterol (r = 0.474, P <0.01), and plasma total triglyceride (r = 0.413, P <0.05). Multiple regression analysis showed that the VLDL1-cholesterol concentration was an independent variable de.
termining the magnitude of the CETP activity. In addition, in these 29 subjects, CETP activity and LCAT activity were correlated (r = 0.452, P <0.01). No relation was found between the plasma LCAT activity and the plasma lipid and lipoprotein concentrations.
DiscussIon
Factors such as age, sex, body weight, diet, and concomitant disease are thought to play an important role in the expression of HFD (2, 18), although the relative importance of these factors has not been analyzed in detail. In the present study, we compared the clinical and biochemical characteristics of sex-and age-matched patients with HFD and subjects with NFL). None of patients with HFD was substantially overweight, reported unusual dietaiy habits, or showed clinical and biochemical signs of concomitant disease. Moreover, no significant differences were observed between HFD patients and NFD subjects with regard to body mass index, dietary habits, and routine laboratory tests (Table 1) 
talipoproteinemia.
The differences in the NFD and HFD lipoprotein profiles were mainly quantitative.
The concentrations of VLDL1, VLDL2, and IDL were moderately increased in subjects with NFD and markedly increased in patients with HFD. The cholesteryl ester content of these lipoprotein (sub)fractions was greater in HFD than in NFL), and the plasma activities of CETP and LCAT were higher in HFD than in NFD. Patients with HFD had lower HDL-cholesterol concentrations than did normolipidemic controls, but HDL-cholesterol concentrations in subjects with NFD and norinolipidemic controls were not significantly different. Taken together, the magnitude of the lipoprotein abnormalities is greater in HFD than in NFD, except for LDL-cholesterol, which is markedly decreased in patients with HFD, but even more so in subjects with NFD ( Table 2) .
The results of the present study emphasize the importance of functionally normal apoE in the regulation of the LDL concentration, the [41] [42] [43] and the data presented here are compatible with this hypothesis.
Interestingly, earlier in vitro studies (44, 45) 
